Citigroup reaffirmed their buy rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research report sent to investors on Thursday, Briefing.com Automated Import reports.

A number of other brokerages also recently commented on BMRN. TheStreet downgraded shares of BioMarin Pharmaceutical from a c- rating to a d+ rating in a research note on Tuesday, May 7th. Cantor Fitzgerald reaffirmed a buy rating and set a $131.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, April 2nd. Wedbush set a $127.00 target price on shares of BioMarin Pharmaceutical and gave the stock a buy rating in a research note on Tuesday, February 26th. Zacks Investment Research downgraded shares of BioMarin Pharmaceutical from a hold rating to a sell rating in a research note on Friday, March 1st. Finally, Robert W. Baird set a $120.00 target price on shares of BioMarin Pharmaceutical and gave the stock a buy rating in a research note on Friday, April 26th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the stock. BioMarin Pharmaceutical has a consensus rating of Buy and a consensus price target of $116.00.

BMRN stock traded up $1.60 during trading on Thursday, reaching $88.57. 826 shares of the stock were exchanged, compared to its average volume of 1,073,849. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.83 and a quick ratio of 2.76. BioMarin Pharmaceutical has a 1 year low of $79.13 and a 1 year high of $106.74. The company has a market capitalization of $15.86 billion, a PE ratio of -268.24 and a beta of 1.46.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, April 25th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. BioMarin Pharmaceutical had a negative net margin of 5.90% and a negative return on equity of 2.97%. The company had revenue of $400.70 million for the quarter, compared to the consensus estimate of $389.95 million. During the same period in the previous year, the firm earned $0.12 earnings per share. BioMarin Pharmaceutical’s quarterly revenue was up 7.3% compared to the same quarter last year. Sell-side analysts forecast that BioMarin Pharmaceutical will post -0.04 EPS for the current year.

In related news, SVP Brian Mueller sold 2,953 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, April 5th. The shares were sold at an average price of $94.00, for a total value of $277,582.00. Following the completion of the transaction, the senior vice president now owns 13,660 shares in the company, valued at $1,284,040. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Daniel K. Spiegelman sold 13,473 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $89.00, for a total transaction of $1,199,097.00. Following the completion of the transaction, the chief financial officer now owns 47,510 shares of the company’s stock, valued at approximately $4,228,390. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 100,011 shares of company stock valued at $8,945,008. Company insiders own 1.90% of the company’s stock.

Several hedge funds have recently made changes to their positions in BMRN. Doyle Wealth Management acquired a new position in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $26,000. Rational Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical by 3,211.1% in the first quarter. Rational Advisors LLC now owns 298 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 289 shares in the last quarter. Commonwealth Bank of Australia grew its holdings in shares of BioMarin Pharmaceutical by 49.6% in the fourth quarter. Commonwealth Bank of Australia now owns 350 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 116 shares in the last quarter. Lindbrook Capital LLC acquired a new position in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $30,000. Finally, PRW Wealth Management LLC acquired a new position in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $30,000.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Story: How do CD ladders protect against rising interest rates?

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.